Rifaximin plus lactulose versus lactulose alone for reducing the risk of HE recurrence.
Hepatol Commun
; 8(6)2024 06 01.
Article
in En
| MEDLINE
| ID: mdl-38727685
ABSTRACT
BACKGROUND:
The aim was to examine rifaximin plus lactulose efficacy in patients with cirrhosis at a risk of developing overt HE who were stratified by important baseline characteristics such as comorbid ascites or diabetes.METHODS:
Pooled post hoc subgroup analysis of adults receiving rifaximin 550 mg twice daily plus lactulose or lactulose alone for 6 months in a phase 3 randomized, double-blind trial and a phase 4 open-label trial was conducted. RESULTS ANDCONCLUSION:
Rifaximin plus lactulose was more efficacious than lactulose alone for reducing the risk of overt HE recurrence and HE-related hospitalization in adults grouped by select baseline disease characteristics.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Recurrence
/
Gastrointestinal Agents
/
Hepatic Encephalopathy
/
Drug Therapy, Combination
/
Rifaximin
/
Lactulose
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Hepatol Commun
Year:
2024
Document type:
Article
Affiliation country:
Country of publication: